deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02158520

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Randomized Phase II Study of AB (Nab-Paclitaxel [Abraxane?], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma

Sponsor: Academic and Community Cancer Research United

Conditions Metastatic Melanoma Mucosal Melanoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Uveal Melanoma AJCC v7 Unresectable Melanoma
Interventions Bevacizumab Ipilimumab Laboratory Biomarker Analysis Nab-paclitaxel Pharmacological Study
Updated 14 times since 2017 Last updated: Jan 7, 2020 Started: Oct 18, 2013 Primary completion: May 24, 2017 Completion: Oct 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02158520, this PHASE2 trial focuses on Metastatic Melanoma and Mucosal Melanoma and remains completed. Sponsored by Academic and Community Cancer Research United, it has been updated 14 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Dec 2019 · 7 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  3. May 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Buffalo, United States , Chapel Hill, United States , Chicago, United States , Grand Rapids, United States , Green Bay, United States , Iowa City, United States , Jacksonville, United States , Madison, United States , Omaha, United States , Rochester, United States and 3 more locations